Related Experiment Videos
Dipyrone metabolism in liver disease
E Zylber-Katz1, Y Caraco, L Granit
1Clinical Pharmacology Unit, Hadassah Univeristy Hospital, Jerusalem, Israel.
Clinical Pharmacology and Therapeutics
|August 1, 1995
Summary
Dipyrone metabolism is impaired in patients with cirrhosis, leading to prolonged elimination of its key metabolites. This study highlights reduced disposition of dipyrone
Area of Science:
- Pharmacokinetics
- Drug Metabolism
- Hepatology
Background:
- Dipyrone is a common analgesic, antipyretic, and anti-inflammatory drug.
- Oral dipyrone is metabolized into 4-methylaminoantipyrine, 4-aminoantipyrine, 4-formylaminoantipyrine, and 4-acetylaminoantipyrine.
- Chronic liver disease, such as cirrhosis, can significantly alter drug metabolism and disposition.
Purpose of the Study:
- To investigate the pharmacokinetic disposition of dipyrone metabolites in patients with cirrhosis.
- To compare the metabolism of dipyrone in cirrhotic patients with healthy young and elderly individuals.
- To assess the impact of chronic liver disease on the elimination half-life and clearance of dipyrone's active metabolites.
Main Methods:
- 12 hospitalized patients with cirrhosis and 27 healthy subjects (young and elderly) received a single 1 gm oral dose of dipyrone.
- Blood and urine samples were collected over 72 hours post-administration.
- Plasma and urine concentrations of four dipyrone metabolites were quantified using High-Performance Liquid Chromatography (HPLC).
Main Results:
- The terminal elimination half-life (t1/2 beta) of 4-methylaminoantipyrine was significantly prolonged in cirrhotic patients compared to young and elderly healthy subjects.
- Clearance for the production of 4-formylaminoantipyrine was reduced in patients with cirrhosis.
- Pharmacokinetic parameters for 4-aminoantipyrine and 4-acetylaminoantipyrine, including prolonged half-lives and decreased clearance, were observed in cirrhotic patients across different acetylation phenotypes.
Conclusions:
- The disposition of key dipyrone metabolites (4-methylaminoantipyrine, 4-aminoantipyrine, 4-formylaminoantipyrine, and 4-acetylaminoantipyrine) is significantly reduced in patients with chronic liver disease (cirrhosis).
- Single oral dose dipyrone administration reveals impaired metabolic pathways in cirrhotic individuals, necessitating potential dose adjustments or careful monitoring.
- Findings underscore the importance of considering liver function when prescribing dipyrone, particularly in patients with cirrhosis.